Form 8-K - Current report:
SEC Accession No. 0000950170-24-091227
Filing Date
2024-08-06
Accepted
2024-08-06 08:39:04
Documents
12
Period of Report
2024-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K inzy-20240806.htm   iXBRL 8-K 40585
2 EX-99.1 inzy-ex99_1.htm EX-99.1 145867
  Complete submission text file 0000950170-24-091227.txt   316997

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inzy-20240806.xsd EX-101.SCH 25817
14 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20240806_htm.xml XML 4880
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 241177239
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)